MOLOGEN AG: Issuance of first tranche of convertible bonds pursuant to existing agreement

MOLOGEN AG / Key word(s): Corporate Action

MOLOGEN AG: Issuance of first tranche of convertible bonds pursuant to existing agreement

01-March-2018 / 16:46 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Publication of an insider information pursuant to Section 17 of the regulation (EU) No. 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

MOLOGEN AG: Issuance of first tranche of convertible bonds pursuant to existing agreement

Berlin, 1 March 2018 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200, SIN 663720) (the “Company”) today requested the Luxembourg-based financing provider European High Growth Opportunities Securitization Fund (the “Investor”) to subscribe the first tranche of up to 24 tranches of convertible bonds. MOLOGEN is to receive an amount of EUR500,000 for this first tranche consisting of ten convertible bonds, each with a par value of EUR50,000.

As announced in the ad-hoc notification on 20 February 2018, MOLOGEN entered into an agreement with the Investor, a fund advised by Alpha Blue Ocean Advisors. Pursuant to this agreement the Company can, over the period of two years having started on 20 February 2018, require the Investor to subscribe for convertible bonds of the Company in an aggregate amount of up to EUR12 million. The bonds will be issued in up to 24 tranches of EUR500,000 each at the Company’s request, whereby the Company will have to observe a waiting period of at least 10 trading days after the issuance of each tranche before requesting the issuance of a new tranche.

The Investor can convert the bonds at its discretion into shares, the conversion being mandatory upon the lapse of 12 months (end of term) from the issuance of the relevant tranche. The conversion price is the Volume Weighted Average Price (VWAP) of the Company’s share during the three trading days preceding the conversion minus a discount of 10% – as applied for the current capital increase with subscription rights of the Company, but at least 80% of the VWAP of the Company’s share during the ten trading days preceding the issuance of the bonds. The subscription price amounts to EUR2.3054 par value per new share and equals the VWAP of the Company’s share during the ten trading days preceding the issuance of the bonds. The bonds shall accrue no interest.

Important note:
This announcement is not an offer of securities for sale in the United States, Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this press release have not been, and will not be, registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offering of the securities in the United States of America. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

– End of the ad-hoc notification –

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 – 30 – 84 17 88 – 38
Fax: +49 – 30 – 84 17 88 – 50
investor@mologen.com

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.


01-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this